Exenatide once a week assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine
The test should be interpreted with a qualified healthcare provider alongside clinical thyroid markers, antibody levels, and inflammatory profiles
Quality of life improvement was greater with PLC (MD 0.06, 95% CI 0.05 to 0.07
She adds that there is a critical need to define subtypes based on combinations of variables to begin to personalize the treatments. Pasinetti adds that by defining a biologically distinct subtype of patients with depression, the use of LAC as a biomarker may identify individuals who may specifically benefit from individualized mechanistic treatments. He adds that this is important to consider, as certain treatments may be more appropriate for specific subgroups of patients, and supports expanding research into individualized treatments for patients with depression. Nasca is hopeful, adding that their latest study opens the possibility of using a panel of biomarkers to identify and study novel therapeutic targets related to central glutamatergic dysfunction in specific subtypes. Russo says that, LAC is not going to be the end-all-and-be-all of depression. Pasinetti agrees that depression is a multifactorial disease that depends upon a complex mosaic of environmental and genetic factors. However, both agree that these translational findings into LAC levels are very exciting, with Dr
